Document Detail

Control of cyclosporine A-induced tumor progression using 15-deoxyspergualin for rat cardiac transplantation.
MedLine Citation:
PMID:  17700170     Owner:  NLM     Status:  MEDLINE    
Immunosuppressive therapy increases the risk of recurrence of initial cancers in organ transplant patients, and compelling therapeutic protocols are needed to suppress the malignancy and protect the allograft. We examined the potential use of 15-deoxyspergualin (DSG) in relation to organ transplantation and cancer. The effect of DSG on established liver metastatic tumors in recipient rats bearing a heart allograft was evaluated using an in vivo luminescent technique with luciferase-expressing RCN-H4 rat colon cancer cells. The inhibition of cell growth by DSG was correlated with NF-kappa B activity and caspase-3/7 activity in vitro. In the cyclosporine A (CsA)-induced cancer progression model of rats, DSG treatment (3 mg/kg) blocked the increase in tumor-derived luciferase activity, while CsA (15 mg/kg) facilitated luciferase activity up to around day 20 after cardiac transplantation. Our data suggest that DSG may be a therapeutic candidate for the control of tumor growth in transplant patients.
Ichiro Ohsawa; Shinji Uemoto; Eiji Kobayashi; Takashi Murakami
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Transplantation     Volume:  84     ISSN:  0041-1337     ISO Abbreviation:  Transplantation     Publication Date:  2007 Aug 
Date Detail:
Created Date:  2007-08-16     Completed Date:  2007-09-26     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0132144     Medline TA:  Transplantation     Country:  United States    
Other Details:
Languages:  eng     Pagination:  424-8     Citation Subset:  IM    
Division of Organ Replacement Research, Center for Molecular Medicine, Jichi Medical University, Tochigi, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Caspase 3 / metabolism
Caspase 7 / metabolism
Cell Proliferation / drug effects
Colonic Neoplasms / enzymology,  pathology
Cyclosporine / adverse effects*,  therapeutic use
Disease Progression
Graft Survival / drug effects
Guanidines / adverse effects,  therapeutic use*
Heart / drug effects
Heart Transplantation / adverse effects*,  immunology,  pathology
Immunosuppressive Agents / adverse effects*,  therapeutic use*
Liver / drug effects
Liver Neoplasms / chemically induced*,  pathology,  prevention & control*
Luciferases / metabolism
NF-kappa B / metabolism
Rats, Inbred F344
Rats, Inbred Lew
Reg. No./Substance:
0/Guanidines; 0/Immunosuppressive Agents; 0/NF-kappa B; 59865-13-3/Cyclosporine; 84937-45-1/gusperimus; EC 1.13.12.-/Luciferases; EC 3.4.22.-/Caspase 3; EC 3.4.22.-/Caspase 7

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Nitrosative stress and corneal transplant endothelial cell death during acute graft rejection.
Next Document:  Sequential quadruple immunosuppression including sirolimus in extended criteria and nonheartbeating ...